Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slipped 4.66% to $5.52 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the Phase 1 trial of CRB-913 for the treatment of obesity ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company currently valued at $71 million, announced on Thursday that Dr. Peter Salzmann has decided not to seek re-election to ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company currently valued at $71 million, announced on Thursday that Dr. Peter Salzmann has decided not to seek re-election ...

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% over the past four weeks, the stock looks well positioned for a trend ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company with a market capitalization of $77 million, announced on Monday the appointment of Ian Hodgson as the new Chief ...